Guidance and quality standards Awaiting development

Skip to filters Skip to results

Showing 11 to 20 of 25

lung cancerRemove lung cancer filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance and quality standards awaiting development
Title	Type
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced or unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]	Technology appraisal guidance
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer ID 6399	Technology appraisal guidance
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage ID6412 small-cell lung cancer TS ID 11975	Technology appraisal guidance
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]	Technology appraisal guidance
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]	Technology appraisal guidance
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]	Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436	Technology appraisal guidance
Serplulimab with chemotherapy for untreated extensive-stage small-cell lung cancer [ID6346]	Technology appraisal guidance
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer TS ID 11951	Technology appraisal guidance
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]	Technology appraisal guidance

Results per page

10
25
50
All